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Abstract: The increasing frequency of multi-drug resistant microorganisms has driven 
research into alternative therapeutic strategies. In this respect, natural antimicrobial peptides 
(AMPs) hold much promise as candidates for the development of novel antibiotics. 
However, AMPs have some intrinsic drawbacks, such as partial degradation by host 
proteases or inhibition by host body fluid composition, potential toxicity, and high 
production costs. This review focuses on the hepcidins, which are peptides produced by the 
human liver with a known role in iron homeostasis, as well by numerous other organisms 
(including fish, reptiles, other mammals), and their potential as antibacterial and antifungal 
agents. Interestingly, the antimicrobial properties of human hepcidins are enhanced at acidic 
pH, rendering these peptides appealing for the design of new drugs targeting infections that 
occur in body areas with acidic physiological pH. This review not only considers current 
research on the direct killing activity of these peptides, but evaluates the potential application 
of these molecules as coating agents preventing biofilm formation and critically assesses 
technical obstacles preventing their therapeutic application. 
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1. Introduction 
Nowadays, microbial resistance to antibacterial and antifungal drugs has reached critical levels, 
invalidating the therapeutic efficacy of a large proportion of molecules currently used in the clinic [1,2]. The 
scenario is particularly alarming in hospitals, where the emergence and rapid spread of microorganisms 
resistant to diverse classes of antimicrobial drugs (Multidrug-Resistant—MDR—strains) have an enormous 
impact on morbidity and mortality as well as on healthcare costs [1,2].  
The increment in the rate of resistance of clinically relevant microorganisms has paralleled a 
progressive reduction in the number of antibiotics approved for clinical use over the past 30 years [3]. 
Therefore, to address this unforeseen threat, extensive research efforts focused on the development of 
new antimicrobial compounds and new strategies for combating multidrug-resistant microorganisms 
represent a top priority in medicine [4]. 
Among future anti-infective drugs under development, antimicrobial peptides (AMPs) have been 
repeatedly proposed as a valid alternative to antibiotics [5–7]. These are a large and diverse group of 
ubiquitous molecules, referred to as effectors of the innate immune system of organisms belonging to 
different levels of the evolutionary scale, and involved in the first line of defense against infectious 
agents [8]. In addition to their generally fast and strong antimicrobial activity, these molecules are often 
able to modulate immune response, recruit immune cells to the infectious site, and neutralize bacterial 
endotoxin suggesting that, in vivo, besides the direct killing of microorganisms, they can indirectly 
participate to the eradication of infections [7]. These characteristics, together with the fact that AMPs 
are less prone to induce the development of resistance compared to conventional antibiotics, render these 
molecules lead compounds for anti-infective agent development. Several drawbacks, however, still limit 
AMP clinical use as systemic drugs, while their use as topical agents to treat muco-cutaneous infections 
seems more feasible. 
The present review focuses on the antimicrobial properties of hepcidins, AMPs produced by a large 
variety of living organisms and endowed with a range of biological activities. In particular, based on our 
previous studies and findings from other research groups, we provide evidence that human hepcidins 
display interesting features that suggest the possible use of these molecules, or their optimized derivatives, 
as future drugs to treat microbial infections of mucosal surfaces with acidic physiological pH. 
2. Antimicrobial Peptides and Their Potential as Novel Antimicrobial Compounds 
AMPs are short (typically 12–100 residues) positively charged (from +2 to +9) molecules, depending 
on their amino acidic composition [9]. AMPs play a key role in the first line immune defense in a wide 
range of organisms, including plants, protozoa, arthropods, insects, fish and mammals [10,11]. 
Depending on their secondary structure, AMPs fall within four main classes; alpha-helical peptides, 
beta-sheet peptides, extended peptides, and loop peptides [12]. Regardless of the specific structure, 
several interesting features suggest that AMPs may be a promising class of potential antimicrobial 
agents. Indeed, AMPs have been proven to exert an antimicrobial action versus bacteria, but also versus 
virus, fungi and protozoa; notably, many of them are active against multi-drug resistant bacteria [8,13–15]. 
To date, approximately 2500 AMPs (natural and synthetic) are listed in the Antimicrobial Peptide 
Database (http://aps.unmc.edu/AP/main.php).  
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AMP microbicidal activity often relies on the electrostatic interaction between the positively charged 
peptide and the negatively charged microbial surface, which leads to AMPs accumulation and 
subsequent infiltration in the membrane [16]. According to this model, AMPs often present rapid killing 
kinetics together with a low tendency for selecting resistance [16]. The cationic nature of AMPs is also 
involved in their preferential binding to microbial membranes. In fact, many bacterial pathogen bilayers 
are highly electronegative, due to the presence of negative molecules (e.g., phosphatidylglycerol, 
phosphatidylserine), while mammalian membranes are usually enriched in zwitterionic phospholipids 
(e.g., phosphatidylcoline, phosphatidylethanolamine). Several negatively charged phospholipids, such 
as phosphatidylinositol and diphosphatidylglycerol, confer also to fungal membranes a negative net 
charge that attracts peptides. A further contribution to AMPs selective toxicity may be due to the 
different transmembrane potential (ΔΨ) between bacterial (from −90 to −110 mV) and host (−130 to 
−150 mV) cells. All these factors make mammalian membranes less prone to interact with AMPs [17].  
AMPs may form permanent or transient pores in the lipid bilayer, as well as induce micelle release in 
a detergent-like manner, and/or cross the membrane without significant damage. [18–21]. Growing 
evidence indicates that AMPs mode of action may be actually influenced by additional factors, including 
pH, peptide concentration and salt abundance. Consequently, it is not unusual that a peptide that is reported 
to induce membrane permeabilization at high concentrations may reach intracellular targets without 
disrupting the lipid bilayer at lower concentration, or in different pH conditions [22–24]. 
The AMPs that do not directly target the cell membrane accumulate in the intracellular compartment, 
interfering with several essential processes and leading to: (i) impairment of DNA, RNA, protein or cell 
wall synthesis; (ii) interaction with intracellular enzymatic targets; (iii) release of oxygen species with 
consequent triggering of apoptosis and (iv) activation of signaling cascades following receptor-mediated 
uptake [22–28]. 
In addition to their antimicrobial activity, AMPs are known to be involved in immunomodulation. In 
fact, many AMPs have been proven to stimulate and/or hamper inflammatory response, induce cell 
migration and/or proliferation, and promote the wound healing process [7]. For this reason, AMPs are 
often referred to as host defense peptides (HDPs). In mammals, the mature protein is usually generated by 
proteolytic cleavage of a pro-peptide [10,12,29]. These genes are expressed in many cell types (e.g., 
monocytes/macrophages, neutrophils, epithelial cells and keratinocytes) either constitutively or following 
inflammatory stimuli [30,31]. In addition, the expression of many AMPs increases following injury and/or 
skin infection, accordingly to the role that this class of molecules plays in wound healing [32]. 
AMPs also play a plastic role in the modulation of the inflammatory response: they can recruit innate 
and adaptive immune effector cells (e.g., monocytes/macrophages, immature dendritic cells, neutrophils 
etc.), either directly or indirectly (by inducing chemokines/cytokines production), depending on their 
concentration [7,10,12,33]. On the other hand, AMPs can trigger the expression of anti-inflammatory 
genes and simultaneously shut down several pro-inflammatory pathways [12,34]. It has been 
hypothesized that this dual action may be involved in balancing the inflammatory process potentially 
triggered by commensal flora antigens [7]. 
Therefore, the broad-spectrum antimicrobial activity of AMPs, together with the plasticity of action 
at the interface between innate and adaptive immunity, make these molecules promising candidates for 
future therapeutic applications.  
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3. Hepcidins: A Conserved Class of Natural Peptides with Antimicrobial Activity 
The liver expressed antimicrobial peptide (LEAP-1) hepcidin is a natural host defence peptide 
produced by humans and originally detected in plasma and urine [35,36]. Two predominant forms have 
been isolated from urine, each composed of 20 and 25 amino acids and only differing by  
N-terminal truncation [35,36]. The structures of hepcidin-20 (hep-20) and -25 (hep-25) present a 
distorted β-sheet shape with a hairpin loop and are stabilized by disulfide pairing of Cys residues and 
hydrogen bonds between the two antiparallel strands (Figure 1). 
 
Figure 1. Molecular structure of hepcidin-20 and hepcidin-25. The cartoon representation 
of hep-20 structure is coloured in rainbow from the N- to the C-terminal portion, with 
disulfide bonds shown as lines (panel A, left side). Two distorted beta sheets are stabilised 
by 8 disulfide bonds, one of which notably occurs between adjacent cysteines at the hairpin 
turn (vicinal S-S bond). Hep-25 shows the same overall structure than hep-20, but it has 5 
additional N-terminal residues; three of them (aspartic acid, threonine and histidine, coloured 
in red, orange, and cyan, respectively) are involved in the formation of the Cu2+-Ni2+ 
(ATCUN)- binding motif (panel A, right side). Panel B shows hep-20 and hep-25 (left and 
right side, respectively) surfaces coloured according to hydrophobicity (decreasing from red 
to white). Due to the distribution of the side chains, the convex face of both hepcidins is 
hydrophobic, whereas the concave one hosts positively charged residues, leading to a marked 
amphipaticity. Notably, the lacking of the first N-term residues reduces hep-20 hydrophobic 
character comparing to hep-25, making this form less prone to aggregation and therefore 
more active against microbes [37]. Molecular graphics created with PyMOL (The PyMOL 
Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC) using hep-20 and hep-25 
NMR structures from the Protein Data Bank (www.rcsb.org; PDB file codes 1M4E and 
1M4F, respectively, [37]). 
B 
A 
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This results in a marked amphipathic peptide structure, a conserved hallmark of many antimicrobial 
and antifungal peptides (Figure 1). The 84-amino acid hepcidin pre-pro-peptide contains a typical 
endoplasmic reticulum targeting signal sequence and a consensus cleavage site for pro-hormone 
convertases. The pre-pro-peptide is successively cleaved to yield pro-hepcidin (35aa) and the mature 25 
amino acid hepcidin. Both the bioactive 25-aa hepcidin and the 35-aa pro-region are secreted by liver 
hepatocytes [38]. A metal-binding site is also present in the amino terminal region of the iron regulator 
hepcidin-25, the so-called Amino‒Terminus‒Copper‒Nickel binding site (ATCUN) motif, 
corresponding to the three first amino acids, which have been associated with the peptide ability to 
interact with ferroportin [39,40]. 
Human hepcidin has been demonstrated to act as an iron regulatory hormone, as well as to exert a 
wide spectrum antimicrobial activity [38]. Several homologues have been identified in other mammals, 
including horse, buffalo, camel, sheep, mouse [41–45], as well as in other vertebrates, such as fish, 
amphibians and reptiles [46].  
A conserved sequence similarity over independent evolution of fish and mammals clearly indicates 
that this gene is vitally important for these organisms. It is known that mutations in the human hep-25 
gene are related with pathologies such as human hereditary hemochromatosis [47], indicating that this 
peptide plays a prominent role in the regulation of iron concentration. In mammals iron sequestration is 
an innate host defence mechanism that limits the availability of this important element and prevents its 
uptake by invading microorganisms [46,47]. For example, it has been shown that horses experimentally 
infected with Streptococcus zooepidermidis show a decrease in serum iron levels, which drop before the 
onset of other clinical signs. Based on experimental data, equine serum iron levels have been used for 
monitoring the severity of inflammation [48,49]. 
Studies based on structural similarity between hepcidin from mammals and other organisms along 
the evolutionary scale, have led to the hypothesis that the iron-regulatory hormone has most likely 
evolved from an antimicrobial peptide during vertebrate evolution [50]. Indeed, the antibacterial activity 
was the first clue leading to the discovery of hepcidin peptides, which highlighted the wide spectrum 
activity versus many pathogenic bacteria and disclosed their important role in the innate immune 
response of fish [50,51]. 
A conserved role in the immune response of organisms along the evolutionary scale implies structure 
similarities conserved and shared by different hepcidin homologues isolated from different organisms. 
As shown in Figure 2, the primary structures of mature hepcidin from higher and lower vertebrates share six 
to eight conserved cysteine residues in key positions, indicating that the disulfide bridges of hepcidin have 
been evolutionarily conserved and may relate to peptide biological function [52]. 
In this respect, it has been shown that intact disulfide bonding pattern is not essential for the regulation 
of iron homeostasis by human hep-25, but rather it plays an important role in the peptide stability in 
biological fluids [52]. 
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Figure 2. Comparison of mature hepcidin amino acidic sequence in different species. 
Sequence alignment was based on GeneBankTM accession numbers using Geneious 
software (http://www.geneious.com) [53]. Percent identity is color coded: bright green 
represents 100% identity, green-brown represents 30%–100%, while red indicates an 
identity score below 30%). Position of the four highly conserved disulfide bridges is 
indicated with orange lines, connecting the eight involved cysteine residues. 
4. Antimicrobial Activity of Human Hepcidins 
4.1. Antibacterial Activity 
The antibacterial properties of human hepcidins were described for the first time by two groups, using 
different antimicrobial susceptibility techniques [35,36]. Using a radial diffusion assay Krause and 
coworkers observed a dose-dependent inhibitory effect of hep-25 against the Gram-positive species 
Bacillus megaterium, B. subtilis, Micrococcus luteus, Staphylococcus carnosus, and the Gram-negative 
species Neisseria cinerea [35]. A colony count assay in sodium phosphate buffer was used by Park and 
coworkers to evaluate the bactericidal activity of hep-25 and its analogue hep-20 [36]. Both peptides 
exhibited antimicrobial properties against Escherichia coli and, to a lesser extent, against S. epidermidis, 
S. aureus, and group B streptococci [36]. More recently, we investigated the antibacterial activity of both 
hep-25 and its analogue hep-20 against a wide array of Gram-positive and Gram-negative multi-drug 
resistant clinical isolates [23]. Both hep-25 and hep-20 were found to be bactericidal at concentrations 
ranging between 3.25 and 50 μg/mL, depending on the bacterial species tested [23]. Among all the 
bacterial species tested, S. aureus was the one exhibiting the highest degree of resistance to both 
hepcidins, suggesting an inherent insensitivity of this microorganism to such peptides. Interestingly, the 
antimicrobial potency of hep-20 was found to be higher than that of hep-25 [23], being the peptide 
bactericidal at lower concentrations than hep-25 against most of the bacterial species tested. Killing 
kinetics of both peptides carried out at neutral pH against Pseudomonas aeruginosa and Enterococcus 
faecium indicated that hep-20 exerted a bactericidal effect in a time interval ranging between 30–60 min, 
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while hep-25 resulted bactericidal not before 60–90 min. Notably, non-bactericidal concentrations of 
hep-20 and hep-25 combined together showed a synergistic antibacterial effect against E. faecium [23], 
suggesting that the two peptides may cooperate in vivo in the innate defense mechanisms to infections. 
In this regard, it has been proposed that the generation in vivo of hep-20 may not simply reflect the 
catabolism of hepcidin, but rather led to the formation of a peptide endowed with more potent 
antibacterial activity compared with hep-25 [23]. 
Antimicrobial properties of the 35 aa hepcidin pro-region have also been demonstrated [38]. In 
particular, this peptide was found to be bactericidal against B. megaterium (25 µM), and showed a 
bacteriostatic effect against B. subtilis, but only at high concentration (200 µM) [38]. 
4.2. Role of the ATCUN Motif  
The N-terminal region of hep-25 represents a metal binding site specific for Cu(II) and Ni(II), known 
as “ATCUN” motif [54]. Although the biological role of a metal binding motif in hep-25 is still 
unknown, its presence is physiologically relevant for the hep-25 iron regulation properties as the first 
five amino acids, starting from the N-terminus, are essential for its interaction with ferroportin [55].  
It is known that the antibacterial activity of some human peptides (e.g., histatin-5,  
peptidoglycan-recognition-protein) is enhanced by the presence of metals, although the underlying 
mechanisms are still unknown [56,57]. To assess the hypothesis that the metal-binding site on hep-25 
could contribute to the bactericidal activity of the peptide we performed antimicrobial susceptibility tests 
in the presence of CuCl2. By sequentially exposing S. aureus and P. aeruginosa cells to hep-25 and then 
to physiological concentration of CuCl2, but not co-incubating the bacteria with hep-25 and CuCl2, a 
statistically significant enhancement of the bactericidal activity of the peptide against both species was 
observed [23]. When the same experiments were carried out using hep-20 no increase of the bactericidal 
activity was observed, supporting the hypothesis that the interaction ATCUN motif—metal does play a 
role in enhancing the antimicrobial activity of hep-25 [23]. The possible mechanism by which CuCl2 
may exert such an effect is not currently known. Interestingly, an ATCUN motif is also present in other 
human histidine-rich peptides (e.g., histatin-5), and it has been reported that high levels of hydrogen 
peroxide are produced in aqueous solutions containing Cu(II), histatin-5, and a reductant, either 
ascorbate or cysteine [54,58,59]. This suggests that the presence of an ATCUN motif may confer to the 
corresponding peptides the ability to generate reactive oxygen species in the presence of metals. 
Assuming that hep-25 is able to cross the bacterial membranes (see below) and reach the intracellular 
milieu, it might be hypothesized that the peptide forms complexes with copper and, in the presence of 
intracellular reductants, may give rise to reactive oxygen intermediates. These, in turn, may induce DNA 
hydrolysis as well as cross-linking and cleavage of bacterial proteins, possibly enhancing the 
antibacterial activity of hep-25 [54,58–60]. 
4.3. Role of Disulfide Bonds  
In human hepcidins disulfide bonds have a fundamental role in maintaining the correct folding of 
peptides [60]. Stabilization of the three-dimensional structure by the intra-molecular disulfide bridges 
seems to be also crucial for the antibacterial activity of these peptides [52]. In fact, when all the cysteine 
residues of hep-25 were replaced by alanines the peptide lost its antibacterial activity [52]. This 
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observation is in contrast with what has been reported for other peptides for which the disulfide bonds 
do not play a role or even represent an obstacle for their antibacterial performances [61,62]. For instance, 
the antimicrobial and cytotoxic activities of the human beta-defensin 3, a peptide with structural 
similarities with hepcidins, are independent on whether and how cysteine residues are arranged to form 
disulfide bonds [61]. In the case of the human beta-defensin 1, only the reduction of the disulfide bridges 
allows the peptide to exert potent antimicrobial properties. In fact, reduced hBD-1 differs structurally 
from oxidized hBD-1 and the free cysteines at the carboxy terminus seem important for the bactericidal 
effect of the peptide [62]. 
4.4. DNA Binding Ability  
It has been demonstrated that hep-25 is able to bind efficiently DNA, even in the presence of high 
concentrations of salts [39,52]. Hep-25 DNA-binding ability seems dependent on the integrity of its 
disulfide bridges as their reduction or replacement of the eight cysteines of the peptides by alanine 
residues led to peptides that are no longer able to bind DNA in in vitro assays [52]. A similar observation 
was also obtained with the hepcidin pro-region that showed a DNA binding ability similar to that 
observed for magainin 2, an AMP known to exert its antimicrobial effect by interfering with intracellular 
nucleic acids [52]. 
4.5. Enhancement of Bactericidal Activity in Acidic Conditions 
One of the most interesting aspects that has emerged from studies examining the antibacterial properties 
of both hep-25 and hep-20 is the net increment of their bactericidal effect in acidic conditions [23]. In 
particular, from 2 to 8 fold reduction of bactericidal concentrations of both hepcidins was observed at 
acidic pH (6.6, 5.8, and 5.0) compared to pH 7.4, paralleling the increment of theoretical net charge of 
the peptides along with pH reduction. Acidic pH (pH 5.0) not only reduced the microbicidal 
concentrations of both hepcidins against both Gram positive (E. faecium) and Gram-negative  
(P. aeruginosa) bacterial species, but also markedly shortened the killing times of both peptides 
compared to pH 7.4 [23]. It is worth noting that by combining very low concentrations of hep-20 and 
hep-25 at pH 5.0 a bactericidal effect could be obtained at peptide levels very close to those measured 
in human serum (range 0.1–4 μg/mL) and urine during infective/inflammatory processes [63,64], 
supporting the hypothesis that hep-25 and/or hep-20 may have in vivo antibacterial functions, other than 
iron regulation properties [23]. 
It has been reported that the presence of histidine residues in the amino acidic sequence of a peptide 
increases its antimicrobial activity at acidic pH [65]. Thus, the marked enhancement of the bactericidal 
activity of hep-20 and hep-25 at pH 5.0 could be due to the presence of histidine residues in the amino 
acid sequence of these peptides. At pH values below pKa of the histidine groups (pKa = 6.5) these 
residues may be protonated, resulting in an increase of the net charge of the corresponding peptide. As 
also suggested for other peptides [65–68], this protonation could facilitate the electrostatic interaction of 
hepcidins with the anionic microbial surfaces and, consequently, improve their antibacterial properties. 
It has been reported that the solubility of a linear form (reduced) of hep-25 is higher at acidic pH (5.5) 
than at neutral pH, suggesting that at low pH values hepcidins may exhibit poor tendency to aggregate 
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with consequent increment in the number of correctly folded molecules, which, in turn, may result in an 
enhanced antimicrobial activity [60]. 
Recently, we investigated the influence of pH on the mode of action of hep-20 and hep-25 against  
E. coli ATCC 25922 and model membranes [24]. By using several experimental approaches, we 
demonstrated that while at acidic pH the peptides cause a rapid and marked permeabilization of bacterial 
and model membranes, no inner membrane perturbation capacity was observed at pH 7.4, even at 
bactericidal concentrations. Scanning electron microscopy studies revealed a different pattern of 
morphological effects caused by both peptides on E. coli cells at neutral and acidic pH. In particular, a 
much higher ability of the peptides to induce bleb formation on the bacterial surface at pH 5.0 than at 
pH 7.4 was observed. This ability has been previously reported for other AMPs such as SMAP-29 [69], 
magainin 2 [70] or temporin L [71] able to act by perturbing the membrane integrity. Based on the data 
obtained in these studies, we hypothesized two not necessarily mutually exclusive hepcidin mechanisms 
of action: at neutral pH, the low membrane-perturbing capacity seen at bactericidal concentrations may 
suggest that an intake of the peptides followed by their interaction with one or more intracellular 
molecular targets (e.g., DNA) is the predominant hepcidins’ mode of action. On the other hand, the 
striking membrane damaging ability exhibited by both peptides at acidic pH, suggests that a classical 
membrane perturbing mechanism is mainly responsible for cell death at pH 5.0. This hypothesis is 
supported by the observation that at pH 5.0 both hepcidins were able to reduce the number of viable  
E. coli cells by 3 log in less than 5 min. Such a rapid killing effect is typical of peptides with a membrane 
targeting mode of action rather than of peptides acting on intracellular targets that exhibit, in general, 
relatively slow bacteria-killing kinetics (from several minutes to some hours) [72]. These findings 
suggest that the mechanism of action of human hepcidins may vary according to pH and may help in the 
development of hepcidin-derived peptides for the local treatment of infections occurring in body districts 
with acidic pH. 
4.6. Antifungal Activity 
The resistance to antifungal therapy observed in some species, either intrinsic or acquired in course 
of treatment, currently represents a major concern in the management of mycoses, thus boosting the 
research for new potential antimicrobial compounds [73]. Hepcidins were first described to possess an 
antifungal activity by Park and co-workers, who demonstrated a direct killing activity against  
Candida albicans and molds like Aspergillus fumigatus and A. niger [36]. 
The last two decades saw a rise in Candida glabrata prevalence, possibly due to the widespread use of 
fluconazole, to which this species is less sensitive than C. albicans and other non-albicans species [74]. This 
emerging pathogen is responsible for both systemic and mucosal infections, being now second in 
frequency only to C. albicans [75,76]. Although many AMPs (e.g., histatins, cathelicidins, defensins, 
and magainin) have been proven to exert antifungal activity versus clinically relevant fungal pathogens, 
C. glabrata seems to be scarcely susceptible to these molecules [77–81].  
Interestingly, we demonstrated that hep-20 exerts in vitro fungicidal effect on a panel of C. glabrata 
clinical isolates with different fluconazole susceptibility [82], while hep-25 did not show any killing 
activity against this species (unpublished results). Following a 90-minute incubation in sodium 
phosphate buffer at pH 7.4, hep-20 minimal fungicidal concentration (MFC) ranged from 50 to 100 μM 
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depending on the strain [82]. Despite the fact that these concentrations are higher than bactericidal ones, 
they are actually comparable to those reported for other antifungal peptides [83]. Most importantly, hep-20 
effect on C. glabrata seems to be enhanced in acidic condition, as already reported for its antibacterial 
activity [23]; indeed, the MFC drops to 25 μM for most strains tested at pH 5.0. Moreover, under acidic 
condition the killing time of the peptide was also shortened, with a fungicidal effect occurring between 
30 and 60 min, compared to kinetics at pH 7.4, where it occurred not earlier than 60–90 min [82]. Since 
a further interesting characteristic of many AMPs is their ability to act synergistically with traditional 
antimicrobial compounds, the effect of hep-20 in combination with amphotericin B, caspofungin or 
fluconazole in acidic condition was also evaluated. Non-fungicidal combination of hep-20 and 
amphotericin B resulted in a significantly enhanced fungicidal effect in comparison with the most active 
component alone, after 24-hour incubation [82]. Similarly, an increase in fungicidal activity could be 
observed for hep-20/caspofungin combination, with a synergistic effect occurring at 90 min and being 
maintained later on [82]. A synergistic effect of the hep-20/fluconazole combination could be detected 
too (in sub-inhibitory concentration each, 50 μg/mL hep-20 + 64 μg/mL fluconazole), as stated by a FICI 
value of 0.5 [82]. 
The enhanced activity of hep-20 observed under acidic conditions suggested that this peptide could 
be used as a therapeutic agent in the topical treatment of recurrent vulvovaginal candidosis due to  
C. glabrata [75,84]. In addition to the scarce susceptibility to azole drugs commonly used in the 
treatment of mucosal infections, a rising number of both fluconazole and echinocandins resistant isolates 
of C. glabrata has been recently documented [85,86]. As a result, vaginal infections due to this species 
are difficult to eradicate and often end up in recurrent episodes, thus highlighting the need for new 
therapeutic strategies [75]. As already mentioned, despite all the interesting features of AMPs, there are 
several limitations holding back their application, including the significant reduction of their activity in 
biological fluids due to physiological concentrations of salt [87–90]. 
Accordingly, it was not surprising that hep-20 activity was found to be impaired in a vaginal fluid 
simulant (VFS) resembling human secretion; in this condition, only the highest peptide concentration 
tested induced a significant reduction in C. glabrata CFU number, even if it did not reach a fungicidal 
effect. However, the addition of the chelating agent EDTA (1 mM) to VFS significantly enhanced  
hep-20 activity, thus confirming a role for cations in hep-20 activity depletion. To strengthen the 
hypothesis of a potential application of hep-20 in the topical treatment of vaginitis due to C. glabrata, 
the fungicidal activity of this peptide has been evaluated in human vaginal fluid (HVF) collected from 
three healthy donors [91].  
The antifungal activity of hep-20 in HVF seems to be influenced by the biological variability 
occurring between the donors. In fact, while in the case of one donor no antifungal activity was observed 
following a 90-minute incubation at 37 °C, a significant reduction in the number of viable yeasts was 
induced by hep-20 for the other two donors. This could be possibly due to the presence of endogenous 
AMPs (e.g., calcoprotectin, HBD1-2, HNP1-3, and LL-37) synergizing with hep-20, thus overcoming 
the inhibitory effect caused by ions or other fluid components [91–94]. Notably, following the addition 
of 1.5 mM EDTA to the HVF, hep-20 exerted a complete fungicidal effect on C. glabrata at a concentration 
that was a quarter of the one that significantly reduced cell number in VFS for all donors [91]. Overall, 
these encouraging results obtained in HVF support a role of hep-20 as a promising candidate, which 
could be further investigated for the topical treatment of C. glabrata vaginal infections.  
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5. Hep-20 Cytotoxicity and Stability 
Even though hep-20 is a human-derived peptide, therapeutically active concentrations could be higher 
than those found at physiological levels. Therefore, it was essential to investigate the potential cytotoxic 
effects exerted by this peptide on human cells. Our data report a lack of hemolytic effect on human 
erythrocytes [82]. Moreover, hep-20 cytotoxicity was evaluated by measuring the effect of different 
peptide concentrations on human PBMC and a human-derived epithelial cell line (A549) by PI staining 
and XTT reduction assay. All hep-20 concentrations tested (6.25 to 100 μM) gave negligible or no 
cytotoxic effect on peripheral blood mononuclear cells and A549 cell line, as demonstrated by PI staining 
and XTT assay [91]. These results are in agreement with a study by Park and coworkers in which  
hep-20 was tested for cytotoxicity on erythroleukemia type K562 human cells (88% viable cells post 
treatment) [36]. For what concerns the stability of the peptide in human fluids, no information is available 
to date on hep-20 half-life in humans. However, indirect evidence on hep-25 clearance from human 
plasma has been obtained, revealing that hep-25 levels decrease over time, with a mean plasma 
elimination half-life ranging between 5 and 8 h [95]. 
6. Inhibition of Biofilm Formation 
Biofilms are defined as complex communities of microorganisms living attached to biotic or abiotic 
substrates and enclosed in a self-produced polymeric extracellular matrix [96]. It is now clear that 
biofilm formation is responsible for a large proportion of infections in developed countries, especially 
in the hospital setting [97]. Examples of biofilm-associated infections are periodontitis, medical  
device-related infections, pneumonia in cystic fibrosis patients, chronic urinary tract infections, recurrent 
tonsillitis, chronic rhinosinusitis, otitis media or wound infections [98]. Biofilm-associated infections 
represent a serious health-care concern, as they are difficult to prevent, diagnose, and treat [97]. In 
particular, biofilm treatment is particularly challenging as biofilms usually exhibit a severely reduced 
susceptibility to antimicrobials due to several mechanisms. These include: reduced diffusion or 
sequestration of antimicrobials through the extracellular matrix, low growth rate of biofilm cells, 
presence of dormant cells virtually tolerant to all drugs [96].  
Due to the peculiar features of biofilm communities, the identification of new anti-biofilm drugs, able 
to specifically target the biofilm mode of growth, is highly needed. In this regard, the possible use of 
AMPs as new anti-biofilm agents is an emerging area of research [99,100]. A large number of AMPs 
with different structures and physical-chemical properties have been tested against bacterial/fungal 
biofilms with promising results [101–104]. 
An updated list of biofilm-active AMPs and related references can be found at www.baamps.it 
website, which was recently developed with the objective to collect data present in the literature on 
AMPs specifically tested against microbial biofilms [105]. 
One of the leading nosocomial bacterial pathogens, whose pathogenicity is significantly linked to its 
ability to form biofilms on medical devices (e.g., central venous catheters, artificial heart valves, or 
prosthetic joints), is Staphylococcus epidermidis. S. epidermidis biofilms form according to a well-defined 
multistep process that involves attachment to a surface, production of accumulation factors that allow 
cell-to cell adhesion, maturation, and detachment of single or clustered cells with colonization of 
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surrounding sites or invasion of blood stream [106]. One of the best studied S. epidermidis accumulation 
factors is the polysaccharide-intercellular-adhesin (PIA), a polymer of β-1,6-linked N-acetyl-glucosamine 
with partially N-deacetylated amine groups, whose synthesis and secretion is under the control of the ica 
operon [106]. Recent epidemiological studies have reported that even PIA-negative strains might exhibit 
marked biofilm forming ability, with proteins being the main accumulation factor in these strains [107]. 
The antibacterial properties of hep-20 have recently been investigated in vitro against biofilms of a 
number of S. epidermidis strains isolated from central venous catheters or blood [108]. All strains were 
finely characterized for their ability to produce biofilms with extracellular matrix mainly constituted of 
PIA or proteins. A striking ability of hep-20 to inhibit biofilm formation of all the strains, in a dose 
dependent manner, was observed, with no major difference between PIA-positive and PIA-negative 
strains. Interestingly, the anti-biofilm activity of hep-20 was strengthened at the mild acidic pH found 
on the human skin (pH 5.5) as compared to pH 7.4, although pH enhancement of peptide’s anti-biofilm 
activity was far less evident than that previously observed against floating bacteria [23]. Kinetics studies 
showed that the inhibition of biofilm formation by hep-20 started already after 3 h of incubation with  
S. epidermidis cells and that the inhibitory effect continued for at least 16 h after peptide removal [108]. 
The reduction in biofilm biomass of S. epidermidis biofilms exerted by hep-20 paralleled a reduction in 
biofilm metabolic activity, while had only a marginal effect on biofilm-associated viable cells. 
Little is known about the mechanisms of the anti-biofilm action of AMPs, but what is progressively 
emerging is that many AMPs may act with mechanisms that differ by a “classical” microbicidal  
effect [99,109]. These include: (i) inhibition of the initial phase of bacterial adhesion to a surface;  
(ii) stimulation of motility; (iii) inhibition of quorum sensing, the bacterial communication machinery 
that regulates many virulence traits, including biofilm formation; (iv) modulation of gene expression. Of 
note, the anti-biofilm activity of hep-20 was obtained at concentrations far below the MIC (minimal 
inhibiting concentration) values of the peptide suggesting that it could act by a “non classical” mode of 
action. Confocal microscopy studies demonstrated that, in the presence of hep-20, both PIA-positive and 
PIA-negative S. epidermidis strains developed biofilms with an altered architecture and reduced amount 
of extracellular matrix [108]. Interestingly, pre-incubation of S. epidermidis biofilms with hep-20, 
followed by incubation with sub-inhibitory concentrations of vancomycin, caused a statistically 
significant reduction of biofilm-associated viable cells of both PIA-positive and PIA-negative strains, as 
compared to biofilms not pre-treated with hep-20. Overall, these results suggest that hep-20 may exert 
its anti-biofilm activity by interfering with extracellular matrix accumulation and this, in turn, may 
improve diffusion of conventional antibiotics (e.g., vancomycin) through the biofilm layers, pointing to 
a possible use of the peptide in anti-biofilm combinatorial therapies. 
7. From the Bench to the Clinical Setting: Advantages and Obstacles 
The direct application of AMPs to the clinical setting has been hampered due to poor bioavailability, 
pharmacokinetics and high synthesis/manufacturing costs [110]. In order to overcome AMP weaknesses 
several strategies have been developed, including minimizing the peptide length or converting the 
original peptide into a peptidomimetic, a small protein-like chain with an altered chemical structure 
appropriately designed to increase stability or biological activity of the peptide and to reduce the peptide 
susceptibility to proteases [111,112]. Information on the selected peptide biochemical, biological and 
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pharmacological properties is an essential prerequisite for modifying the native peptide into a promising 
novel drug. To this end, computer-assisted AMP design programs provide an accurate prediction of the 
“cidal” effect possessed by the modified peptide or peptidomimetic [113]. Nevertheless, in the case of 
hepcidins, the activity of which is strongly dependent upon disulfide bridges, this might not be the ideal 
choice, since it could be difficult to predict the exact rate of correct folding of the synthetic peptide. In 
addition, disulfide rich peptides, like hepcidins, are difficult to prepare, since they require extensive 
redox folding procedures to achieve the creation of four disulfide bridges. Moreover, they tend to 
aggregate, giving rise to a poor yield. 
Other strategies include the multimerization of AMPs, where multiple copies of a given peptide are 
assembled around a core molecule, with the aim of increasing the peptide activity [114]. Multivalent 
peptides have been shown to possess strong antifungal properties [115,116]. 
Encapsulation of AMPs in small drug carriers offers the double effect of protecting the peptide from 
premature degradation, and of ensuring a local delivery of the compound. In recent years, nanocarriers, 
such as liposomes, dendritic polymers, solid core nanoparticles, carbon nanotubes have been developed, 
which are able to be captured by several cell types [117] and can be engineered to deliver the appropriate 
peptide content with a targeting moiety carefully designed for different applications [118–120]. This 
could represent a promising approach for a tailored delivery of hepcidin into the host. 
Finally, another interesting approach under evaluation is the possibility of using AMPs as coating 
agents to prevent colonization/infection of medical devices. It is renowned that catheter-associated 
infections are often caused by microbial colonization on prosthetic materials, which in turn hampers an 
efficient eradication of the infection. In this respect, biofilm producing microorganism create an ideal 
niche for their survival, with the extracellular matrix protecting sessile cells and often contributing to the 
development of a drug resistant phenotype. Hep-20 could represent promising agent in inhibiting biofilm 
formation on plastic surfaces, since it is small enough to penetrate the exopolysaccharide matrix, has a 
wide spectrum activity and good biocompatibility. The previously reported ability of hep-20 to interfere 
with extracellular matrix accumulation of relevant biofilm forming microorganisms looks promising for 
the identification of future combinatorial therapies of the peptide with bactericidal compounds aimed at 
eradicating biofilm on prosthetic materials. 
8. Hepcidin 20 as a Potential Drug for Future Use 
The rise in drug resistance among clinically relevant microorganism has triggered the study of 
alternative therapeutic strategies. AMPs are considered promising candidates for the development of 
novel antibiotics. Among these, human hepcidins show an interesting potential as antimicrobial agents, 
active on both bacterial as well as fungal species. The enhancing effect of low pH on bactericidal activity 
of human hepcidins render these peptides interesting for the development of future drugs specifically 
designed for the treatment of bacterial and/or fungal infections occurring in body districts with acidic pH. 
From this point of view, hep-20 looks particularly promising as, unlike hep-25, the peptide does not seem 
to be involved in iron homeostasis and exerts antimicrobial activity at concentrations generally lower 
than hep-25 [23]. In addition, hep-20 has shown activity against multidrug-resistant fungal strains [82] 
that were insensitive to the inhibitory effects of hep-25 (unpublished results). Both physiological and 
pathological mechanisms are responsible for generating a low pH in vivo. For instance, healthy skin has 
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a normal pH of about 5; it is well established that acidic pH plays a role in skin defense against fungal 
and bacterial infections [121] and that skin disorders, associated with increased cutaneous pH, predispose 
patients to secondary microbial infections. The vagina of reproductive age women is another district 
physiologically maintained at acidic pH (4.0–5.5) by the presence of Lactobacillus spp. and other 
bacteria that produce lactic acid by sugar fermentation [122]. Although differences in species 
composition and relative-abundances of populations in vaginal bacterial communities have been 
described across women from various ethnic backgrounds, low pH is a highly conserved feature and it 
is believed to contribute in restricting the growth of pathogens and other opportunistic organisms [122]. 
The generation of a low pH consequent to the fermentation of dietary sugar by oral bacteria is 
considered a key step in the pathogenesis of dental caries by selecting aciduric bacterial species involved 
in cariogenesis [123]. The urinary tract of most individuals, the gastric mucosa, or the mature phagosome 
following phagocytosis of microbes are all further examples of environments characterized by acidic pHs. 
Interestingly, it has been recently demonstrated that hepcidin is localized in gastric parietal cells, 
regulates acid secretion and is induced by Helicobacter pylori infection [124]. Of note, knockout mice 
with hepcidin-deficiency demonstrated an impaired acid secretion by gastric cells and experienced 
gastric bacterial overgrowth [124]. This finding leads to the intriguing hypothesis that individuals 
genetically less prone to hepcidin production may be more susceptible to H. pylori gastric infection and 
that therapeutical administration of hepcidin in such subjects may restore acid secretion and inhibit 
bacterial growth.  
Another important observation was made by Sow and coworkers, who reported a synergistic 
induction of hepcidin in bone marrow derived mouse macrophages treated with IFN-γ and 
Mycobacterium tuberculosis [125]. The same authors demonstrated that hepcidin localizes to the 
mycobacteria-containing phagosomes and that the peptide possesses an antimicrobial activity against  
M. tuberculosis in vitro [125]. As previously mentioned, the design of hep-20 peptides, chimeric for 
motives driving intracellular penetration (cell-penetrating-peptides) [126], could be an interesting field of 
investigation aimed at the development of new generation of drugs targeting intra-phagosomal bacteria.  
Thus, design of hep-20 based peptides, could be a promising strategy to treat a number of infections 
in disparate body districts and conditions (Figure 3) in view of:  
(i) the high cytocompatibility of such peptides [82,91],  
(ii) the ability to specifically be more active at acidic pH [23,24,82,91], 
(iii) the possibility to act synergystically with other endogenously produced peptides [91], 
(iv) their activity against a wide range of multidrug-resistant bacterial and fungal strains [23,82,91].  
Nevertheless, difficulties in synthesis, due to the need of disulfide bridges for maintenance of 
antimicrobial activity [51], partial inhibition by body fluids [90], and relatively high active 
concentrations, represent possible obstacles for the use of hepcidin-derived peptides as future drugs, 
demanding further bench research for their optimization and use in the clinic as new therapeutics.  
In conclusion, although their clinical application is still hindered by technical obstacles, hepcidin 
modification or innovative delivery formulation will hopefully help us crossing the bridge still existing 
from the bench to the clinic bedside. 
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Figure 3. Body districts characterized by an acidic pH, where hep-20 could express its 
potentiated antimicrobial properties in the control of both bacterial and fungal infections.  
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